Get started
Author

Susana Hernando Polo

Observed names: Susana Hernando POLO, Susana Hernando-Polo
ORCID: 0000-0002-7337-5837
Observed ORCID: 0000-0002-7337-5837
OpenAlex ID: A5108250866
Breast cancer patient experiences through a journey map: A qualitative study
2021 · Laura Ciria-Suarez, Paula Jiménez-Fonseca, et al. · PLoS ONE · 118
PDF
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial
2019 · Ignace Vergote, Giovanni Scambia, et al. · The Lancet Oncology · 95
PDF
Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial
2017 · Jesus García-Donas, Albert Font, et al. · The Lancet Oncology · 50
Psychological distress and resilience in patients with advanced cancer during the Covid-19 pandemic: the mediating role of spirituality
2022 · Luka Mihic-Gongora, Paula Jiménez-Fonseca, et al. · BMC Palliative Care · 32
PDF
Changing the History of Prostate Cancer with New Targeted Therapies
2021 · Susana Hernando Polo, Diana Moreno Muñoz, et al. · Biomedicines · 26
PDF
Mammographic density and breast cancer in women from high risk families
2015 · Teresa Ramón y Cajal, Isabel Chirivella, et al. · Breast Cancer Research · 26
PDF
Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions
2022 · Fernando López-Campos, Pablo Gajate, et al. · Biomedicines · 24
Weekly cabazitaxel plus prednisone is effective and less toxic for ‘unfit’ metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial
2017 · Miguel Ángel Climent, Begoña Pérez-Valderrama, et al. · European Journal of Cancer · 21
Phase II study of dovitinib in first line metastatic or (non resectable primary) adrenocortical carcinoma (ACC): SOGUG study 2011-03.
2014 · Jesús García-Donas, Susana Hernando Polo, et al. · Journal of Clinical Oncology · 15
Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma
2020 · Joaquim Bellmunt Molins, Jesús García-Donas Jiménez, et al. · Clinical Genitourinary Cancer · 14
Ascertaining breast cancer patient experiences through a journey map: A qualitative study protocol
2020 · Laura Ciria-Suarez, Paula Jiménez-Fonseca, et al. · PLoS ONE · 12
PDF
Progression-free survival (PFS) and second PFS (PFS2) by disease stage in patients (pts) with homologous recombination deficiency (HRD)-positive newly diagnosed advanced ovarian cancer receiving bevacizumab (bev) with olaparib/placebo maintenance in the phase III PAOLA-1/ENGOT-ov25 trial.
2021 · Patricia Pautier, Philipp Harter, et al. · Journal of Clinical Oncology · 9
Phase II study of dovitinib in first line metastatic or (nonresectable primary) adrenocortical carcinoma (ACC): SOGUG study 2011-03.
2013 · Jesús García-Donas, Susana Hernando Polo, et al. · Journal of Clinical Oncology · 8
Maintenance vinflunine post cisplatin chemotherapy (CT) in patients with advanced urothelial carcinoma (UC): Preliminary analysis of a randomized placebo controlled phase II trial (MAJA trial)—SOGUG 2011-02.
2015 · Joaquim Bellmunt, Begona Perez Valderrama, et al. · Journal of Clinical Oncology · 5
Vinflunine maintenance therapy versus best supportive care after platinum combination in advanced bladder cancer: A phase II, randomized, open label, study (MAJA study, SOGUG 2011-02)—Interim analysis on safety.
2014 · Susana Hernando Polo, Aranzazu Gonzalez del Alba, et al. · Journal of Clinical Oncology · 5
Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study
2021 · Álvaro Pinto, Oscar Reig, et al. · Clinical Genitourinary Cancer · 4
Randomized, placebo-controlled phase II trial (MAJA): Efficacy results of maintenance vinflunine after cisplatin chemotherapy (CT) in patients with advanced urothelial carcinoma (UC)—SOGUG 2011-02.
2016 · Albert Font, Begoña Perez-Valderrama, et al. · Journal of Clinical Oncology · 4
Open label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: The Greko II study—GETHI 2013-01.
2015 · Jf. Rodriguez-Moreno, Jesús García-Donas, et al. · Journal of Clinical Oncology · 4
Phase II trial of intraperitoneal (IP) administration of catumaxomab (C) as consolidation therapy for patients (pts) with relapsed epithelial ovarian cancer (OC) in second or third complete remission: GEICO 1001 study.
2014 · Ignacio Romero, Ana Oaknin, et al. · Journal of Clinical Oncology · 4
Long-term Clinical Outcomes of a Spanish Cohort of Metastatic Renal Cell Carcinoma Patients with a Complete Response to Sunitinib
2022 · Guillermo de Velasco, Teresa Alonso-Gordoa, et al. · Clinical Genitourinary Cancer · 3
Correlation between time to PSA progression (TTPP), radiographic progression-free survival (rPFS) and overall survival (OS) in first-line abiraterone/enzalutamide (Abi/Enza) and docetaxel (Doc) treated patients in a prospective cohort study.
2019 · David Lorente, Elena Castro, et al. · Journal of Clinical Oncology · 3
Comprehensive molecular and immunohistochemical analysis of advanced renal cell carcinoma patients treated with mTOR inhibitors.
2018 · Jesús GarcÃa-Donas, Jose Maria Roldan, et al. · Journal of Clinical Oncology · 3
Open label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: The Greko II study.
2017 · Jesús García-Donas, Laia Garrigos, et al. · Journal of Clinical Oncology · 3
Weekly cabazitaxel in "unfit" metastatic castration-resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment: Preliminary results of CABASEM-SOGUG phase II trial.
2015 · Ovidio Fernandez Calvo, Eva Fernandez Parra, et al. · Journal of Clinical Oncology · 3
#4934 Hyperthermic Intraperitoneal Chemotherapy With Cisplatin Increases the Risk of Acute Kidney Injury Compared to Conventional Intraperitoneal Cisplatin
2023 · Mariana León-Póo, Teresa Robles Bermejo, et al. · Nephrology Dialysis Transplantation · 2
PDF
Works count: 42
Citation count: 500
H-index: 11
I10-index: 11
Year
Topic
Type